A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER

Brief description of study

If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or metastatic (the spread of) Stage 4 Non-small cell lung cancer (IV-NSCLC), you ay be qualified for this Phase I study. The main goal of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of the investigational drug NKTR-214 given in combination with KEYTRUDA® or TECENTRIQ®.


Clinical Study Identifier: s17-01412
ClinicalTrials.gov Identifier: NCT03138889
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.